Skip to main content

Table 3 Comparison of JIA with no uveitis and with uveitis (JIAU)

From: Paediatric non-infectious uveitis in Cape Town, South Africa: a retrospective review of disease characteristics and outcomes on immunomodulating treatment

Diagnosis JIA Total N = 217 JIA no uveitis N = 203 JIAU N = 14 p-value
Median Age months
(IQR)
111
(54–148)
114.5
(59–152)
55
(34–86)
p = 0.008
Age groups (months) N (%)   Odds Ratio 95% CI
 0–84 70 (32.3) 60 (29.6) 10 (71.4) p = 0.01 0.46 CI 0.25–0.83
 85–144 73 (33.6) 69 (33.9) 4 (28.6) p = 0.78 0.71 CI 0.22–2.35
 145–192 60 (27.7) 60 (29.6) 0 p = 0.01 1.0 CI 0.6–1.7
Female N (%) 135 (62.2) 127 (62.5) 8 (57.1) p = 0.68 0.78 CI 0.26–2.34
Ancestry N (%)
 Mixed 124 (57.1) 114 (56.2) 10 (71.4) p = 0.40 0.72 CI 0.39–1.3
 Black African 37 (17.1) 35 (17.2) 2 (14.3) p = 1.00 1.25 CI 0.27–5.8
 Caucasian 56 (25.8) 54 (26.6) 2 (14.3) p = 0.53 0.46 CI 0.10–2.1
JIA subtype N (%)
 Oligo-articular 83 (38.3) 73 (35.9) 10 (71.5) p = 0.01 4.45 CI 1.35–14.7
 Poly articular RF + 18 (8.3) 18 (8.8) 0 p = 0.61 0.08 CI 0.04–0.13
 Poly articular RF – 43 (19.8) 40 (19.7) 3 p = 1.00 1.05 CI 0.54–2.04
 Psoriatic 16 (7.4) 15 (7.4) 1 p = 1.00 0.99 CI 0.59–1.66
 Systemic Onset JIA 17 (7.8) 17 (8.4) 0 p = 0.61
 Enthesitis Related Arthritis 38 (17.5) 38 (18.7) 0 p = 0.14
 Undifferentiated 2 (0.9) 2 (1) 0 p = 1.00
Lab Parameters N (%)
 ANA tested 147 (67.7) 136 (67) 11 (78.6) p < 0.001 33.29 CI 6.83–162.09
 Hep2 Positive 15 10 5  
 Elisa Positive 15 9 6  
 RF tested 125 (57.6) 116 (57.1) 9 (64.3) p = 0.36
 Negative 107 98 9   
 Positive 18 18 0   
HLA B27 tested
Present
63 (29)
4
62 (30.5)
4
1 (7.1)
0
p = 1.00